Differential diagnosis of Parkinsonism

Canadian Journal of Neurological Sciences

Volumn 26, Issue SUPPL. 2, 1999, Pages

  Stoessl, A Jon ^a   Rivest, Jean ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b CHUS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBON DISULFIDE; CARBON MONOXIDE; CINNARIZINE; CYANIDE; DOMPERIDONE; FLUNARIZINE; HEXANE; MANGANESE; METHANOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; RESERPINE; SOLVENT;

ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DEGENERATIVE DISEASE; DIAGNOSTIC APPROACH ROUTE; DIFFUSE LEWY BODY DISEASE; HUMAN; NEUROTOXICITY; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME;

EID: 0032768510     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100000020     Document Type: Article

References (30)

1. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62: 352-356.
2. Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a mult-infarct state. Neurology 1987; 37: 570-576.
3. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1-9.
4. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990; 113: 1823-1842.
5. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997; 12: 133-147.
6. Savoiardo M, Girotti F, Strada L, Ciceri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm (Suppl ) 1994; 42: 93-110.
7. Rosenberg RN, Fowler HL. Autosomal dominant motor system disorder of the Portuguese. A review, Neurology 1981; 31: 1124-1126.
8. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nature Genetics 1994; 8: 221-228.
9. Koeppen AH. The hereditary ataxias. J Neuropathol Exp Neurol 1998; 57: 531-543.
10. Fitzgerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord 1989; 4: 249-260.
11. Micheli F, Pardal MF, Gatto M, et al. Flunarizine-and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 37: 881-884.
12. Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine-and flunarizine-induced parkinsonism. Mov Disord 1997; 12: 107-110.
13. Nath A, Hobson DE, Russell A. Movement disorders with cerebral toxoplasmosis and AIDS. Mov Disord 1993; 8: 107-112.
14. Factor SA, Podskalny GD, Barron KD. Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. J Neurol Sci 1994; 127: 114-120.
15. Calne DB, Chu NS, Huang CC, Lu CS, Olanow W. Manganism and idiopathic parkinsonism: similarities and differences. Neurology 1994; 44: 1583-1586.
16. Uitti RJ, Snow BJ, Shinotoh H, et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994; 35: 616-619.
17. Tanner CM. Occupational and environmental causes of parkinsonism. Occup Med 1992; 7: 505-513.
18. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, Schneck SA. Diffuse Lewy body disease and progressive dementia. Neurology 1988; 38: 1520-1528.
19. Perry RH, Irbing D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body disease in the elderly. J Neurol Sci 1990; 95: 119-139.
20. Gibb WRG, Luther PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112: 1171-1192.
21. Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40: 1203-1212.
22. Litvan I, Agid Y, Goetz C, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 1997; 48: 119-125.
23. Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184-189.
24. Nagahama Y, Fukuyama H, Turjanski N, et al. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord 1997; 12: 691-696.
25. Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996; 55: 53-67.
26. Kertesz A. Frontotemporal dementia, Pick disease, and corticobasal degeneration. One entity or 3? 1. Arch Neurol 1997; 54: 1427-1429.
27. Lin SK, Lu CS, Vingerhoets FJG, et al. Isolated involvement of substantia nigra in acute transient Parkinsonism: MRI and PET observations. Parkinsonism Rel Disord 1995; 1: 67-73.
28. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in Parkinsonism-a prospective study. Can J Neurol Sci 1991; 18: 275-278
29. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
30. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990; 13: 553-558.